This is a preview of subscription content, log in via an institution to check access.
Notes
Truven Health MarketScan Commercial Claims and Encounters Database, and Medicare Supplemental and Coordination of Benefits database
2012 US dollars
Reference
Baser O, et al. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis. Clinical Therapeutics : 18 May 2015. Available from: URL: http://doi.org/10.1016/j.clinthera.2015.04.012
Rights and permissions
About this article
Cite this article
Switching anti-TNFs less costly than switch to non-TNF biologic. PharmacoEcon Outcomes News 729, 28 (2015). https://doi.org/10.1007/s40274-015-2185-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2185-8